Sanofi Pasteur and Sutro Biopharma will hook up to produce two undisclosed vaccine candidates. A statement offered little insight to the details of the collaboration. "This collaboration highlights the potential value of Sutro's biochemical synthesis technology for the production of vaccines and provides additional validation of the benefits of our technology platform," William Newell, CEO of Sutro, said in a statement. "We are looking forward to expanding our expertise in protein expression into the field of vaccines with an established leader in the area." Release